Lentaron Anti Estrogen Steroids Powder CAS 566-48-3 Formestane

Formestane (Lentaron) is a type I, steroidal aromatase inhibitor. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection. Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity, in addition to acting as a mild aromatase inhibitor. Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified. How Does Formestane Works For Breast Cancer? By significantly reducing estrogen levels in the blood, methanesulfon may exhibit antitumor activity. In a trial involving 147 postmenopausal women and advanced breast cancer drug resistance, 22% of patients received partial response and 20% achieved disease stabilization. [3] In comparing the non-steroidal aromatase inhibitor anastrozole with methotrexate, it was found that anastrozole was more effective and consistent in inhibiting estrogen levels in vivo. However, these results are unproven clinical significance. Formestane is a second generation irreversible steroid aroma inhibitor. It inhibits the aromatase responsible for converting androgen into estrogen, thereby preventing estrogen production. Breast cancer may be estrogen-sensitive or insensitive. Most breast cancers are estrogen-sensitive. Estrogen-sensitive breast cancer cells are dependent on estrogenic activity. Therefore, removal of estrogen from the body can become an effective treatment for hormone-sensitive breast cancer. Formestane is specially designed for the treatment of postmenopausal women. Unlike premenopausal women who produce the most estrogen in the ovaries, postmenopausal women produce most estrogens in peripheral tissues with the help of aromatases. The aromatic compound inhibitor Formestane can help reduce the local production of estrogen by blocking peripheral tissue (ie, aromatase in breast tissue) to treat hormone-sensitive breast cancer.